doi: 10.1016/S1470-2045(21)00027-9 38. Park IH, Im S, Jung KH, Sohn JH, Park YH, Lee KS, et al. Randomized open label phase III trial of irinotecan plus capecitabine versus capecitabine monotherapy in patients with metastatic breast cancer previously treated withanthracycline and taxane: PROCEED trial (KCSG BR 11-01). Cancer Res Treat (2019) 51(1):43 –52.